Zhaoke Ophthalmology’s Low-Dose Atropine Eye Drops Cleared for Evaluation by Australia’s TGA

Bulletin Express

Jun 15

Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration (TGA) has accepted the company’s registration application for its 0.02% Atropine Sulfate Eye Drops (product code: NVK002), designed to slow myopia progression in children and adolescents.

The TGA confirmed on 2 June 2026 that the submission passed its preliminary assessment and will move to full evaluation. Zhaoke’s filing is supported by positive Phase III clinical data, although specific trial metrics were not disclosed in the announcement.

NVK002 employs a proprietary formulation aimed at stabilising low-concentration atropine. According to the company, the preservative-free product carries global intellectual-property protection and delivers a 24-month shelf life.

Management reiterated that successful development or commercialisation is not guaranteed, and cautioned shareholders and potential investors to exercise prudence when dealing in the company’s shares.

The update was released on 15 June 2026 and signed by Chairman Dr. Li Xiaoyi on behalf of the board.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1181639427"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181639427\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181639427?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 12:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181639427","market":"us","top_or_hot":-1,"title":"Zhaoke Ophthalmology’s Low-Dose Atropine Eye Drops Cleared for Evaluation by Australia’s TGA","media":"Bulletin Express","content":"<p>Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration (TGA) has accepted the company’s registration application for its 0.02% Atropine Sulfate Eye Drops (product code: NVK002), designed to slow myopia progression in children and adolescents.</p>\n<p>The TGA confirmed on 2 June 2026 that the submission passed its preliminary assessment and will move to full evaluation. Zhaoke’s filing is supported by positive Phase III clinical data, although specific trial metrics were not disclosed in the announcement.</p>\n<p>NVK002 employs a proprietary formulation aimed at stabilising low-concentration atropine. According to the company, the preservative-free product carries global intellectual-property protection and delivers a 24-month shelf life.</p>\n<p>Management reiterated that successful development or commercialisation is not guaranteed, and cautioned shareholders and potential investors to exercise prudence when dealing in the company’s shares.</p>\n<p>The update was released on 15 June 2026 and signed by Chairman Dr. Li Xiaoyi on behalf of the board.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology’s Low-Dose Atropine Eye Drops Cleared for Evaluation by Australia’s TGA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology’s Low-Dose Atropine Eye Drops Cleared for Evaluation by Australia’s TGA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-15 12:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration (TGA) has accepted the company’s registration application for its 0.02% Atropine Sulfate Eye Drops (product code: NVK002), designed to slow myopia progression in children and adolescents.</p>\n<p>The TGA confirmed on 2 June 2026 that the submission passed its preliminary assessment and will move to full evaluation. Zhaoke’s filing is supported by positive Phase III clinical data, although specific trial metrics were not disclosed in the announcement.</p>\n<p>NVK002 employs a proprietary formulation aimed at stabilising low-concentration atropine. According to the company, the preservative-free product carries global intellectual-property protection and delivers a 24-month shelf life.</p>\n<p>Management reiterated that successful development or commercialisation is not guaranteed, and cautioned shareholders and potential investors to exercise prudence when dealing in the company’s shares.</p>\n<p>The update was released on 15 June 2026 and signed by Chairman Dr. Li Xiaoyi on behalf of the board.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06622","symbol_name":"兆科眼科-B","start_time":0,"source_url":"","article_id":"1181639427","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181639427","pubTimestamp":1781497279,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration (TGA) has accepted the company’s registration application for its 0.02% Atropine Sulfate Eye Drops (product...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06622":"兆科眼科-B"},"translate_title":"兆科眼科低剂量阿托品滴眼液获澳大利亚TGA审评许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1},"content_text":"Zhaoke Ophthalmology Limited announced that Australia’s Therapeutic Goods Administration (TGA) has accepted the company’s registration application for its 0.02% Atropine Sulfate Eye Drops (product code: NVK002), designed to slow myopia progression in children and adolescents.\nThe TGA confirmed on 2 June 2026 that the submission passed its preliminary assessment and will move to full evaluation. Zhaoke’s filing is supported by positive Phase III clinical data, although specific trial metrics were not disclosed in the announcement.\nNVK002 employs a proprietary formulation aimed at stabilising low-concentration atropine. According to the company, the preservative-free product carries global intellectual-property protection and delivers a 24-month shelf life.\nManagement reiterated that successful development or commercialisation is not guaranteed, and cautioned shareholders and potential investors to exercise prudence when dealing in the company’s shares.\nThe update was released on 15 June 2026 and signed by Chairman Dr. Li Xiaoyi on behalf of the board.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}